Viking Therapeutics Advances Obesity Pill as Micro-Caps Struggle With Compliance

The US niche market is experiencing a severe bifurcation as macroeconomic pressures and a higher-for-longer interest rate environment persist. While mid-cap firms are reporting double-digit revenue growth, multiple micro-cap equities valued under USD 50M are relying on reverse stock splits and emergency offerings to maintain their listing status, according to recent regulatory filings and people familiar with the matter.

Data shows that capital is rapidly flowing out of fundamentally weak, fringe assets despite adequate overall market liquidity. Analysts noted that companies like ZHONGCHAO are forced to secure funding at steep discounts, while entities with core pipelines or proven profitability continue to expand their market share.

ZHONGCHAO INC (ZCMD.US)

ZHONGCHAO has underperformed the broader sector this year. In July 2026, the company announced a definitive agreement for a registered direct offering to sell 4.54 million shares at USD 1.10 each, targeting roughly USD 5M in gross proceeds. To maintain its Nasdaq listing, the healthcare information provider implemented multiple reverse splits in the first half of 2026, including 1-for-3 and 1-for-31 ratios, according to people familiar with the company's operations.

XIAO-I CORPORATION (AIXI.US)

Shares of XIAO-I CORPORATION have been under sustained pressure. According to its latest financial report, the cognitive intelligence firm saw its 2025 revenue drop to USD 12.3M, accompanied by a staggering net loss of USD 110M. Despite attempts to curtail spending, the company's SG&A expenses remained stubbornly high at USD 76.6M, highlighting a severe cost structure mismatch.

Blackstone Secured Lending Fund (BXSL.US)

The business development company has pulled back slightly this year. For the first quarter of 2026, BXSL reported net investment income of USD 0.77 per share, exactly covering its dividend distribution. While its investment portfolio yielded 11.7% at fair value, non-accruals jumped to 3.1% from historic lows, raising market scrutiny over its asset quality, according to people familiar with the matter.

Token Cat (TC.US)

Formerly known as TuanChe, Token Cat has struggled with sluggish momentum. Since its 2025 pivot into automotive consumption and crypto assets, the company's operating cash flow over the trailing 12 months dropped to negative USD 25.2M. Regulatory filings show the firm recently filed a USD 500M mixed shelf offering to prepare for future capital maneuvers.

WEIBO CORPORATION (WB.US)

WEIBO has stabilized in recent trading sessions. The social media platform announced a USD 200M share repurchase program to counter market volatility and boost shareholder confidence. The company is slated to report its unaudited second-quarter results on August 19, 2026, with analysts closely monitoring the recovery pace of its advertising business and cost-control metrics.

Surf Air Mobility (SRFM.US)

The air mobility platform has faced a continued downdraft in its share price this year. On July 24, 2026, the company received a delisting warning from the NYSE after its closing price stayed below USD 1 for 30 consecutive trading days. Still, its Q1 report showed total revenue of USD 25.6M, up 9% year-over-year, and the company improved its full-year 2026 adjusted EBITDA loss forecast to a range of USD 25M to USD 30M.

Greenwave Technology Solutions (GWAV.US)

Greenwave is also mired in compliance issues. The metal recycling operator received a non-compliance notice from Nasdaq for failing to file its Q1 2026 10-Q report on time. Financial data showed its Q1 revenue surged 121.9% to USD 16.28M, while its net loss narrowed to USD 1.51M. The company previously executed a 1-for-110 reverse stock split to meet minimum bid requirements.

Viking Therapeutics (VKTX.US)

Viking Therapeutics has surged year-to-date, outperforming the broader market. In late July 2026, the biotech firm reported that the Phase III VANQUISH-1 and VANQUISH-2 trials for its dual GLP-1/GIP receptor agonist, VK2735, were fully enrolled. The company is targeting the fourth quarter of 2026 to initiate late-stage studies for the drug's oral formulation.

Coeur Mining (CDE.US)

Boosted by strong commodity prices, Coeur Mining has recorded significant gains recently. In the first quarter of 2026, the precious metals producer generated USD 856.19M in revenue, up 137.8% year-over-year and well above consensus estimates, while EPS came in at USD 0.36. The company also declared its first-half 2026 dividend of USD 0.02 per share.

TAL Education Group (TAL.US)

TAL Education has shown a robust performance this year. For its first fiscal quarter of 2027 ended May 2026, the company posted a 31.9% jump in revenue to USD 758.4M. Net income attributable to TAL soared to USD 408M, or USD 0.73 per share, easily topping the estimated USD 0.16. The strong penetration of its smart learning solutions served as the core driver for the earnings beat, according to people familiar with management's thinking.

This article does not constitute investment advice.